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Differential metabolic effects of oral
butyrate treatment in lean versus
metabolic syndrome subjects
KEC Bouter1, GJ Bakker1, E. Levin1, AV Hartstra1, RS Kootte1, SD Udayappan1, S. Katiraei2, L. Bahler1, P. W. Gilijamse1,
V. Tremaroli3, M. Stahlman3, F. Holleman4, N. A. W. van Riel1, HJ Verberne5, JA Romijn4, GM Dallinga-Thie1, MJ Serlie6,
MT Ackermans7, EM Kemper8, K. Willems van Dijk2, F. Backhed3, AK Groen1,9 and M. Nieuwdorp1,3,4,10,11
Abstract
Background: Gut microbiota-derived short-chain fatty acids (SCFAs) have been associated with beneﬁcial metabolic
effects. However, the direct effect of oral butyrate on metabolic parameters in humans has never been studied. In this
ﬁrst in men pilot study, we thus treated both lean and metabolic syndrome male subjects with oral sodium butyrate
and investigated the effect on metabolism.
Methods: Healthy lean males (n= 9) and metabolic syndrome males (n= 10) were treated with oral 4 g of sodium
butyrate daily for 4 weeks. Before and after treatment, insulin sensitivity was determined by a two-step
hyperinsulinemic euglycemic clamp using [6,6-2H2]-glucose. Brown adipose tissue (BAT) uptake of glucose was
visualized using 18F-FDG PET-CT. Fecal SCFA and bile acid concentrations as well as microbiota composition were
determined before and after treatment.
Results: Oral butyrate had no effect on plasma and fecal butyrate levels after treatment, but did alter other SCFAs in
both plasma and feces. Moreover, only in healthy lean subjects a signiﬁcant improvement was observed in both
peripheral (median Rd: from 71 to 82 µmol/kg min, p < 0.05) and hepatic insulin sensitivity (EGP suppression from 75 to
82% p < 0.05). Although BAT activity was signiﬁcantly higher at baseline in lean (SUVmax: 12.4 ± 1.8) compared with
metabolic syndrome subjects (SUVmax: 0.3 ± 0.8, p < 0.01), no signiﬁcant effect following butyrate treatment on BAT
was observed in either group (SUVmax lean to 13.3 ± 2.4 versus metabolic syndrome subjects to 1.2 ± 4.1).
Conclusions: Oral butyrate treatment beneﬁcially affects glucose metabolism in lean but not metabolic syndrome
subjects, presumably due to an altered SCFA handling in insulin-resistant subjects. Although preliminary, these ﬁrst in
men ﬁndings argue against oral butyrate supplementation as treatment for glucose regulation in human subjects with
type 2 diabetes mellitus.
Introduction
As a steep increase in the prevalence of obesity is seen
in the Western world, with expectations rising up to about
33% of obese adults that will develop insulin resistance
and ultimately type 2 diabetes mellitus, novel insights in
this epidemic disease are necessary1,2. Unfortunately,
current therapeutic strategies can only partly prevent the
complications associated with insulin resistance, notably
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micro- and macrovascular diseases, and therefore new
treatment modalities are urgently needed3. Recent animal
studies have suggested that intestinal microbiota might
play a metabolic role in weight control and insulin sen-
sitivity4. Elevated generation of the short-chain fatty acids
(SCFAs) butyrate, acetate, and propionate by bacterial
fermentation of dietary ﬁbers is thought to contribute to
systemic energy regulation by decreasing hepatic glucose
and lipid production5 Concomitantly, SFCAs can activate
intestinal G protein-coupled receptors, including GPR 41
and GPR 43, which also improves metabolism6. Recent
data however suggest that depending on metabolic
background these SCFAs might have opposite effects. On
the one hand, rodents on a high-fat diet that develop diet-
induced obesity (DIO) have increased (gut microbiota-
driven) acetate production with concomitant insulin
resistance7. On the other hand, oral supplementation of
butyrate in DIO rodents led to an increase of insulin
sensitivity and energy expenditure8.
Although the exact roles of SCFAs in metabolism are only
partly understood5, recent animal data have suggested that
regulation of brown adipose tissue (BAT) by the SCFA
butyrate9,10 as well as bile acids via FGF1911 can improve
insulin sensitivity and lipid parameters in rodent models of
metabolic disease. The mitochondria in brown adipocytes
contain uncoupling protein-1, which inhibits ATP synthesis
at the expense of heat12. Therefore, enhanced BAT activity is
important for energy expenditure and is considered to be of
inﬂuence on insulin sensitivity13,14. Since BAT activation has
been reported in DIO insulin-resistant mice that were treated
with the oral SCFA butyrate8, we performed a human pilot
study to investigate the effect of 1 month of daily oral sodium
butyrate treatment on hepatic and peripheral insulin sensi-
tivity (as assessed by 2H2-glucose-based two-step hyper-
insulinemic normoglycemic clamp), resting energy
expenditure (REE), and BAT activity in both lean and obese
insulin-resistant males. Based on available animal data we
performed a pilot trial that oral butyrate treatment would
improve insulin sensitivity via activation of BAT in both lean
and metabolic syndrome subjects. We however found that
this intervention was not effective in human metabolic
syndrome.
Methods
Caucasian, healthy, lean (body mass index (BMI) 20–25
kg/m2) males and Caucasian obese males (BMI > 25 kg/
m2) were recruited via local newspaper advertisements.
Participants had to be >18 years old. Those obese subjects
fulﬁlling the National Cholesterol Education Program
(NCEP) criteria for metabolic syndrome (≥3/5: fasting
plasma glucose ≥ 5.6mmol/l; triglycerides (TG) ≥ 1.7
mmol/l; waist circumference > 102 cm; high-density lipo-
protein cholesterol (HDLc) < 1.03 mmol/l; blood pres-
sure ≥ 130/85mmHg; and BMI ≥ 30 kg/m2) were
included15. Exclusion criteria for both groups were a his-
tory of a cardiovascular event, cholecystectomy, use of any
medication known to inﬂuence gut microbial composition
(e.g., proton pump inhibitors, antibiotics, and pro-/pre-/
synbiotics) in the last 3 months as well as medication
inﬂuencing metabolism (e.g., lipid-lowering, antidiabetic,
and/or antihypertensive drugs). All subjects had a stable
weight and dietary intake for 3 months prior to inclusion.
Written informed consent was obtained from all subjects.
The study was approved by the Institutional Review Board
(IRB) and conducted at the Academic Medical Center
(AMC) Amsterdam, The Netherlands, in accordance with
the Declaration of Helsinki. All authors had access to the
study data, reviewed, and approved the ﬁnal manuscript.
Upon inclusion during the winter season (since brown
fat can be measured most reliably during that season)14,
subjects were admitted to the clinical trial unit at the
AMC for a baseline visit (visit 1+ 2) and then started
treatment with 4 g (2 g BID) of sodium butyrate supple-
mentation (Sensilab, Poland), which was the maximum
daily dose allowed by IRB based on a previous human
intervention study16. Compliance was evaluated by
counting the number of capsules returned after 4 weeks of
treatment. Measurements performed at baseline were
repeated in all subjects after 4 weeks (visit 3+ 4) (see
supplemental Fig. 1). Participants were asked to maintain
their habitual physical activity pattern, but to refrain from
heavy exercise in the days preceding the hyperinsulinemic
euglycemic clamp. Participants were encouraged to con-
tinue their usual diet. All participants ﬁlled out an online
nutritional diary (www.dieet-wijzer.nl) to monitor caloric
intake of carbohydrates, fat, protein, and ﬁbers before and
after 4 weeks of butyrate treatment.
Hyperinsulinemic euglycemic clamp
After an overnight fast, REE using indirect calorimetry
was determined. Then, hepatic and peripheral glucose
metabolism was measured at baseline during a two-step
hyperinsulinemic euglycemic clamp using [6,6-2H2]-glu-
cose to measure endogenous glucose production (EGP)
and hepatic and peripheral insulin sensitivity (rate of
glucose disposal (Rd)) as previously described17. EGP and
the peripheral uptake of glucose (Rd) were calculated
using modiﬁed versions of the Steele equations for the
non-steady state18 and were expressed as μmol/kg/min.
BAT activity
BAT activity was determined as described before19. In
short, all subjects were tested during the winter season
after an overnight fast. They were exposed to mild cold
(16 °C–17 °C) in an air-cooled room for 2 h. During the
cold exposure, subjects were wearing underwear only.
After 1 h of cold exposure, the radioactive tracer 18F-FDG
was administered, adjusted for BMI, leading to dosages of
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200MBq; 18F-FDG positron emission tomography-
computed tomography (PET-CT) was performed
directly after the 2-h cold exposure (i.e., 1 h after 18F-FDG
administration). We measured standardized maximal
uptake (SUVmax), mean uptake (SUVmean), and volume
of BAT. Each BAT volume was measured using a 18F-
FDG threshold-based delineation. Therefore, volumes
measured reﬂect activated BAT volume. All visually
identiﬁed areas with active BAT were included in the
analysis. All analyses were done by a single person (L.B.).
Biochemistry
Fasting glucose (Hitachi), insulin (Diagnostic products),
C-reactive protein (Roche, Switzerland), free fatty acid
(FFA; Wako), and lipopolysaccharide-binding protein
(LBP, HyCult) were determined in fasted plasma samples.
Total cholesterol, low-density lipoprotein cholesterol
(LDLc), HDLc, and TG were determined in EDTA-
containing plasma using commercially available enzy-
matic assays (Randox, Antrim, UK and DiaSys). All ana-
lyses were performed using a Selectra autoanalyzer
(Sopachem, The Netherlands). FFA concentrations were
determined with an enzymatic colorimetric method
(NEFA-C test kit; Wako Chemicals, Neuss, Germany)
Insulin was determined on an Immulite 2000 system
(Diagnostic Products, Los Angeles, CA, USA). Fasting
glucagon was determined with the Linco 125I RIA (Linco
Research, St Charles, MO, USA). FGF19 was determined
by a commercial enzyme-linked immunosorbent assay
(Quantikine Human FGF-19 Immunoassay). Fasting
plasma bile acid proﬁles were measured using liquid
chromatography tandem mass spectrometry (LC-MS/MS)
as previously described20. On the last 2 days of the week
before the start and 4 weeks after oral butyrate treatment,
subjects were asked to collect 24 h feces (stored at 4 °C)
for fecal bile acid composition using gas chromatography
as described21, including the primary bile acids cholic acid
and chenodeoxycholic acid as well as the secondary bile
acids deoxycholic acid, lithocholic acid (LCA), urso-
deoxycholic acid, and iso-LCA. The total amount of pri-
mary and secondary bile salts was calculated as the sum of
the individually quantiﬁed bile salts22. SCFA concentra-
tions (acetate, butyrate, and propionate) and lactate were
determined in overnight-fasted EDTA plasma and in fresh
morning fecal samples using LC-MS/MS23.
Fecal micobiota analyses
Total genomic DNA was isolated from feces as pre-
viously described23. Fecal microbiota composition was
proﬁled by sequencing the V4 region of the 16S rRNA
gene on an Illumina MiSeq instrument (llumina RTA
v1.17.28; MCS v2.5) with 515F and 806R primers designed
for dual indexing and the V2 Illumina kit (2 × 250 bp
paired-end reads). 16S rRNA genes from each sample
were ampliﬁed in duplicate reactions in volumes of 25 μL
containing 1× Five Prime Hot Master Mix (5 PRIME
GmbH), 200 nM of each primer, 0.4 mg/mL bovine serum
albumin, 5% dimethylsulfoxide, and 20 ng of genomic
DNA. PCR was carried out under the following condi-
tions: initial denaturation for 3 min at 94 °C, followed by
25 cycles of denaturation for 45 s at 94 °C; annealing for
60 s at 52 °C and elongation for 90 s at 72 °C; and a ﬁnal
elongation step for 10min at 72 °C. Duplicates were
combined, puriﬁed with the NucleoSpin Gel and PCR
Clean-up kit (Macherey-Nagel), and quantiﬁed using the
Quant-iT PicoGreen dsDNA kit (Invitrogen). Puriﬁed
PCR products were diluted to 10 ng/μL and pooled in
equal amounts. The pooled amplicons were puriﬁed again
using Ampure magnetic puriﬁcation beads (Agencourt) to
remove short ampliﬁcation products. Illumina reads were
merged using PEAR24 and ﬁltered by removing all reads
that had at least one base with a q-score lower than 20.
Final reads were analyzed with the software package
QIIME (version 1.8.0). Sequences were clustered into
operational taxonomic units (OTUs) at a 97% identity
threshold using an open-reference OTU-picking
approach with UCLUST against the Greengenes reference
database (13_8 release)25. All sequences that failed to
cluster when tested against the Greengenes database were
used as input for picking OTUs de novo. Representative
sequences for the OTUs were Greengenes reference
sequences or cluster seeds, and were taxonomically
assigned using the Greengenes taxonomy and the Ribo-
somal Database Project Classiﬁer26. Representative OTUs
were aligned using PyNAST and used to build a phylo-
genetic tree with FastTree which was used to calculate α-
and β-diversity of samples using Phylogenetic Diversity
and UniFrac27. Three-dimensional principal coordinate
analysis (PCoA) plots were visualized using Emperor28.
Chimeric sequences were identiﬁed with ChimeraSlayer29
and excluded from all downstream analyses. Similarly,
OTUs that could not be aligned with PyNAST, singletons,
and low-abundant OTUs with a relative abundance <
0.002% were also excluded. To correct for differences in
sequencing depth, a same amount of sequence was ran-
domly sub-sampled from each sample (30 000 sequences/
sample); therefore, a total of 1 886 870 sequences and
1181 OTUs were included in the diversity analyses.
Statistical analyses
Differences in clinical variables between lean and Met-
Syn subjects were tested with unpaired T-test or
Mann–Whitney test depending on normality of the data.
Moreover, paired T-test or Wilcoxon test were used for
differences within groups. Linear correlations between
SCFAs were calculated using Spearman’s correlation
coefﬁcients. A p-value < 0.05 was considered signiﬁcant.
With regard to fecal microbiota analyses, relative OTU
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abundances were calculated as previously described23.
Subsequently, signiﬁcantly dissimilarities in gut micro-
biota composition between individuals before and after
treatment were assessed with the Bray–Curtis (β-diver-
sity) index calculated at the OTU and at the genus level by
Mann–Whitney test. The Bray–Curtis dissimilarities were
plotted using unconstrained PCoA allowing to visualize
the dimensions explaining most variability in the
dissimilarity matrix and tested using multivariate non-
parametric analysis of variance30. Moreover, to study
whether speciﬁc OTUs were discriminating between lean
and MetSyn groups before and after treatment we used
elastic net algorithm modeling as recently published31,32
In short, a randomization test was conducted to test the
statistical validity of the results obtained with the elastic
net algorithm. The dataset containing information on
assignment of the subjects to lean or MetSyn group was
randomly reshufﬂed while the corresponding microbial
proﬁles were kept intact. This was repeated multiple times
and the area under receiver-operating characteristic
(ROC) curve (AUC) scores (see supplemental Fig. 2) were
generated each time by application of the elastic
net algorithm to the permuted data. As a test statistic, the
ROC AUC score was chosen with the null hypothesis that
there is no difference in microbial proﬁle between the
conﬁrmed metabolic syndrome and lean groups. Corre-
lation plots were made using R statistical software. Mul-
tivariate statistical modeling was done using Numerical
Python and MATLAB.
Results
A total of 20 male subjects (10 healthy lean males and
10 males with metabolic syndrome) were included. One
lean subject was excluded from the analyses due to
technical difﬁculties with clamp and PET-CT. Therefore,
19 subjects were available for analysis (Table 1). As
expected, baseline age, BMI, REE, blood pressure, fasting
lipids, glucose, and insulin were signiﬁcantly different
between lean controls and metabolic syndrome subjects.
Following butyrate treatment, a signiﬁcant increase in
plasma total cholesterol and LDLc was observed only in
the metabolic syndrome group (Table 1).
Effect of oral sodium butyrate treatment on plasma and
fecal SCFAs
At baseline, subjects with metabolic syndrome showed a
different composition of plasma SCFA, with a lower
percentage of acetate and higher percentages of propio-
nate and butyrate (Table 2a) compared to the lean





Before After Before After
Age (years) 25 ± 2.4 42 ± 2.4#
Body mass index (kg/
m2)
22.1 ± 2.4 21.9 ± 2.0 33.2 ± 3.6# 33.1 ± 3.6
Systolic blood
pressure
129 ± 9 121 ± 13 139 ± 16 146 ± 24
Diastolic blood
pressure
74 ± 7 69 ± 9 82 ± 7* 79 ± 16
Heart rate (bpm) 64 ± 11 62 ± 10 66 ± 6 64 ± 7
Cholesterol (mmol/l) 4.2 ± 0.8 4.2 ± 0.8 4.9 ± 0.7* 5.2 ± 0.8^
HDLc (mmol/l) 1.4 ± 0.2 1.4 ± 0.3 1.0 ± 0.2# 1.1 ± 0.2
LDLc (mmol/l) 2.2 ± 0.5 2.2 ± 0.5 2.8 ± 0.5* 3.0 ± 0.5^
TG (mmol/l) 0.8 ± 0.3 0.7 ± 0.2 1.8 ± 0.3# 1.7 ± 0.2
FFA (mmol/l) 0.5 ± 0.2 0.5 ± 0.1 0.5 ± 0.2 0.5 ± 0.1
REE (kcal/day) 1728 ± 157 1776 ±
200
1938 ± 214 1854 ± 322
Energy intake (kcal/
day)
1884 ± 705 1753 ±
520
1916 ± 425 1966 ± 324
Values are expressed as means +/− SD
Differences between lean and metsyn subjects were tested with unpaired T-test
or Mann–Whitney test based on Gaussian distribution (*p < 0.05, #p < 0.01).
Moreover, paired T-test or Wilcoxon test was used for differences within groups
(^p < 0.05)
HDLc high-density lipoprotein cholesterol, LDLc low-density lipoprotein choles-
terol, TG triglycerides, REE resting energy expenditure
Table 2a SCFA concentrations in plasma before and after oral butyrate supplementation
Group Time point Total SCFA (μM) Acetate (μM) Acetate (%) Propionate (μM) Propionate (%) Butyrate (μM) Butyrate (%)
Lean 0 117.7 ± 44.7 106.1 ± 42.9 89.6 ± 3.6 8.5 ± 3.3 7.6 ± 3.1 3.1 ± 0.9 2.8 ± 0.7
Lean 4w 115.2 ± 40.5 103.7 ± 36.2 90.2 ± 2.8 7.3 ± 3.8 6.3 ± 2.3 4.3 ± 3.4 3.5 ± 1.8
MetSyn 0 79.9 ± 68.6 68.6 ± 20.7 85.6 ± 2.8* 8.2 ± 2.7 10.4 ± 2.8* 3.2 ± 1.0 4.0 ± 0.8**
MetSyn 4w 67.7 ± 28.2 59.0 ± 25.5 86.9 ± 5.0 5.6 ± 2.6# 8.6 ± 3.9 3.1 ± 2.8 4.5 ± 3.2
Short-chain fatty acid (SCFA) concentrations in plasma were measured before and after butyrate supplementation in healthy lean males (Lean) and obese insulin-
resistant males (MetSyn). Data are presented as mean ± standard deviation
* Represents a statistically signiﬁcant difference at baseline between the Lean and MetSyn groups, *p < 0.05; **p < 0.01. # Represents a statistically signiﬁcant
difference between time point 0 and time point 4w (4 weeks), p < 0.05
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subjects. There were no baseline differences in fecal SCFA
concentrations between the two groups (Table 2b). In
contrast, 4 weeks of oral butyrate supplementation
affected the fecal SCFA concentrations to a greater extent
than plasma levels. Whereas the plasma propionate con-
centration was signiﬁcantly decreased in the MetSyn
group after butyrate treatment compared to baseline, in
feces we found a signiﬁcant reduction o total SCFA,
acetate, propionate, and butyrate concentrations in the
MetSyn group after 4-week butyrate supplementation.
Finally, fasting plasma lactate levels were increased at
baseline in insulin-resistant subjects compared to lean
subjects, but remained largely unaffected upon butyrate
treatment in both groups (metabolic syndrome: from 0.6
± 0.1 to 0.6 ± 0.1 versus lean: from 0.4 ± 0.2 to 0.4 ± 0.1
mmol/l), whereas fecal concentrations of lactate were not
altered upon butyrate treatment (lean: from 1.1 ± 0.6 to
1.1 ± 0.3 versus insulin resistant: from 1.4 ± 0.5 to 1.6 ±
0.9 μmol/g feces, ns).
Effects of oral sodium butyrate on glucose metabolism
As expected, metabolic syndrome subjects were char-
acterized by markedly impaired hepatic and peripheral
insulin sensitivity as compared to healthy lean control
subjects (Fig. 1). In lean healthy males, there was a sig-
niﬁcant improvement in peripheral insulin sensitivity (Rd:
from 71 ± 10 to 82 ± 16 µmol/kg min, p < 0.05) after
4 weeks’ oral butyrate while no change was observed in
the metabolic syndrome subjects (Rd: from 33 ± 10 to 31
± 9 µmol/kg min, ns; see Fig. 1a and supplemental
Table 1). In line, a signiﬁcant improvement in hepatic
insulin sensitivity (expressed as % EGP suppression) was
observed in lean healthy males (from 75 ± 7 to 82 ± 8%, p
< 0.05), while no effect was observed in the metabolic
syndrome group (from 60 ± 7 to 58 ± 11%, ns; Fig. 1b and
supplemental Table 1).
Effects of oral sodium butyrate on BAT activation and bile
acid metabolism
In line with previous reports13,14,20, BAT activity at
baseline was signiﬁcantly higher in lean subjects
(SUVmax: 12.4 ± 1.8) when compared to metabolic syn-
drome subjects (SUVmax lean: 0.3 ± 0.8, p < 0.01). Upon
4 weeks of oral sodium butyrate supplementation BAT







Acetate (%) Propionate (μmol/
g)
Propionate (%) Butyrate (μmol/
g)
Butyrate (%)
Lean 0 326.7 ± 226.5 206.8 ± 153.3 62.4 ± 3.0 69.3 ± 64.5 7.6 ± 3.1 50.7 ± 20.7 17.6 ± 5.6
Lean 4w 191.3 ± 82.8 118.8 ± 50.3 63.0 ± 10.4 41.1 ± 23.3 6.3 ± 2.3 31.4 ± 26.3 16.2 ± 8.4
MetSyn 0 340.6 ± 141.9 208.3 ± 97.6 60.1 ± 7.9 78.3 ± 36.9 10.4 ± 2.8 54.0 ± 23.9 16.2 ± 4.1
MetSyn 4w 226.9 ± 129.0## 139.8 ± 85.3# 61.9 ± 9.7 44.5 ± 25.9## 8.6 ± 3.9 42.5 ± 34.8# 17.9 ± 8.5
Short-chain fatty acid (SCFA) concentrations in feces were measured before and after butyrate supplementation in healthy lean males (Lean) and obese insulin-
resistant males (MetSyn). Data are presented as mean ± standard deviation
# Represents a statistically signiﬁcant difference between time point 0 and time point 4w (4 weeks), #p < 0.05; ##p < 0.01
















































































Fig. 1 Effect of oral sodium butyrate on peripheral insulin sensitivity
and hepatic insulin sensitivity in both lean and metabolic syndrome
subjects. The effect of oral butyrate treatment in lean subjects and
metabolic syndrome subjects on a peripheral (Rd or glucose rate of
disappearance) and b hepatic insulin sensitivity (% suppression of EGP).
Data are presented as median plus interquartile range. Differences
between lean and MetSyn subjects were tested with Mann–Whitney test
and Wilcoxon test for differences within groups
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activation was not affected in either lean healthy males
(SUVmax: from 12.4 ± 1.8 to 13.3 ± 2.4) or in metabolic
syndrome subjects (SUVmax: from 0.3 ± 0.8 to 1.2 ± 4.1,
ns). With respect to bile acid metabolism fasting plasma
levels of FGF19 were signiﬁcantly higher at baseline, in
lean (FGF19: 133 ± 64 pg/mL) than in MetSyn subjects
(FGF19: 88 ± 36 pg/mL, p < 0.05). In line, lean subjects
were characterized by lower plasma primary and sec-
ondary bile acids in both plasma and feces when com-
pared to MetSyn subjects (see supplemental table 2).
However in both groups, oral butyrate treatment had
neither an effect on FGF19 levels (lean: to 123 ± 64 and
MetSyn: to 66 ± 31 pg/mL, ns) nor on primary and sec-
ondary bile acids in both plasma and 24 h feces (see
Supplementary table 2).
Effects of oral sodium butyrate on fecal microbiota and
clinical correlations
At baseline no signiﬁcant difference was observed in
bacterial (β) diversity between lean and metabolic syn-
drome subjects; also oral butyrate treatment had no sig-
niﬁcant effect (Simpsons diversity index lean: from 0.97 ±
0.02 to 0.97 ± 0.02 versus MetSyn: from 0.95 ± 0.01 to
0.95 ± 0.02, ns; Fig. 2a, b). Using multivariate analyses, we
did not observe an effect of oral butyrate treatment on
overall fecal microbiota composition at 4 weeks in both
lean and MetSyn subjects. However, when applying our
recently published elastic net algorithm31,32 to identify the
intestinal bacterial species most discriminative between
lean and MetSyn groups following oral butyrate treatment
(Fig. 2c) we could with high sensitivity (AUC 0.88, also see
supplemental Fig. 2) identify Lachnospiraceae and Bac-
teroides (in lean) and Coriobacteriaceae and Clostridiales
cluster XIVa (in metabolic syndrome) to be the most sig-
niﬁcantly affected by butyrate treatment (p < 0.05).
Subsequent correlation analyses revealed that in lean
subjects these Bacteroides species in fecal samples were
signiﬁcantly correlated with both pre- and posttreatment
plasma butyrate levels (Fig. 3a). However in metabolic
syndrome subjects, Coriobacteriaceae species in fecal
samples were signiﬁcantly correlated with both pre- and
posttreatment hepatic insulin sensitivity (suppressed
EGP), whereas an inverse signiﬁcant correlation with
plasma LDLc and butyrate levels was seen (Fig. 3b).
Finally, in lean subjects fecal acetate levels were sig-
niﬁcantly correlated with fecal butyrate and propionate
levels in both pre- and post oral butyrate treatment feces,
whereas these correlations were not found in metabolic
syndrome subjects.
Discussion
Recent observational studies have supported a role for
decreased intestinal SCFA butyrate-producing bacterial
strains in human insulin resistance5,23, yet interventional
studies are lacking. To our knowledge this is the ﬁrst
human pilot study studying oral butyrate supplementation
on human glucose and BAT metabolism. Although we
were unable to detect any increases in butyrate con-
centration in the feces or plasma after 4 weeks of treat-
ment, other SCFAs were differentially altered between
both treatment groups. Moreover and in contrast to lean
subjects, we observed that oral butyrate supplementation
did not result in improved glucose metabolism in the
metabolic syndrome subjects, who would be the most
logical treatment group
The SCFAs, acetate, propionate, and butyrate make up
the majority of SCFAs and are present within the colonic
lumen in a molar ratio of 3:1:1, predominantly generated
by fermentation of dietary ﬁbers5. Whereas the proximal
colon has a function in saccharolytic fermentation (e.g.,
generation of SCFAs), the distal colon mainly drives
proteolytic fermentation (e.g., generation of p-cresol)5. In
a recent study systemic availability of SCFA in healthy
humans was shown to be 36%, 9%, and only 2% for acetate,
propionate, and butyrate, respectively33. In line with other
human data using rectal infusions of SCFA34–36, intestinally
produced SFCA proprionate is a known preferred pre-
cursor for gluconeogenesis, whereas acetate and butyrate
are involved in regulation of cholesterol synthesis, a cor-
relation that is also found in our study (Fig. 3)37. Once
SCFAs have been generated in the colon, they are sub-
jected to a high intestinal inter-conversion in the intestine
of healthy subjects38. Unfortunately, we did not observe
large changes in butyrate concentrations in the feces or
plasma after 4 weeks of supplementation, most likely
because most of the butyrate is very quickly utilized as an
energy source by intestinal epithelium. Nevertheless,
other SCFA levels were altered and correlated with mar-
kers of insulin sensitivity in metabolic syndrome patients
(Fig. 3b) suggesting different handling and ﬂux of these
SCFAs in the obese insulin-resistant state. In support of
this hypothesis, a peroxisome proliferator-activated
receptor γ-dependent switch from hepatic lipid synthesis
to increased energy utilization was seen only in obese
(DIO) mice8,39. In line with Fig. 3, altered SCFA substrate
preference has been previously shown in healthy lean
subjects33,40–43 in whom colonic SCFA propionate is
used as a gluconeogenic substrate while concomitantly
inhibiting the utilization of acetate for cholesterol synth-
esis44,45. Moreover, in line with tracer data derived from
rodent studies more than half a century ago46, we spec-
ulate that intestinally produced SCFA are differentially
handled in the obese insulin-resistant state in order to
regulate glucose and lipid metabolism45. In contrast with
animal work47, we observed no relation between butyrate
supplementation and bile acid metabolism. Although
further research is needed, we did ﬁnd some associations
between metabolic parameters including SCFA levels and
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Fig. 2 Effect of oral sodium butyrate on microbiota composition in both lean and metabolic syndrome subjects. Changes in fecal microbiota
composition before and after butyrate in either a lean (dark and light blue dots, respectively) or b MetSyn subjects (dark and light green dots,
respectively) as depicted by PCA biplots based on Bray–Curtis (left panel), unweighted unifrac (middle panel), and weighted unifrac (right panel). c
Signiﬁcant associations between changes in fecal bacterial strains (depicted on the y-axis) between lean and metabolic syndrome (depicted on x-axis)
after 4 weeks of butyrate treatment; a positive weight represents an association with butyrate treatment in lean subjects, whereas a negative weight
represents an association with butyrate treatment in metabolic syndrome subjects. The higher the weight, the stronger the association
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speciﬁc intestinal bacterial strains (Fig. 3) suggesting a
potential role of speciﬁc intestinal bacterial strains48,49 in
this altered SCFA handling between healthy and insulin-
resistant human subjects.
Our study has certain limitations. First, our ﬁndings are
derived from a small pilot study of both healthy lean and
obese insulin-resistant male Caucasian subjects in whom
butyrate was released in the small intestine rather than in
the colon50. As metabolic syndrome takes several years to
develop1, subjects with metabolic syndrome were sig-
niﬁcantly older than lean controls. Second, the butyrate
dose used was lower than the 5% of bodyweight quantities
of butyrate usually given in mouse studies8,37 Based on
previous literature16, we had to keep a maximum daily
oral dose of 4 g/day. At this used amount, peripheral
insulin sensitivity improved only in the lean despite
similar dose and compliance in both lean and metabolic
syndrome groups. As we did not adjust our daily dose of
oral butyrate as amount/kg bodyweight in our study, this
might have also resulted in a sub-therapeutical dose of
sodium butyrate in the more obese metabolic syndrome
subjects. Thus, larger follow-up (placebo) controlled trials
with different dose ranges are needed in different degrees
of insulin resitance (e.g., metabolic syndrome versus overt
type 2 diabetes). Moreover, as SCFA levels in feces and
plasma are hard to measure reliably due to their volatile
nature, future human studies combining oral with intra-
venously administered stable isotope-labeled SCFA are
warranted to accurately monitor ﬂuxes33 in order to
validate our ﬁndings and to further unravel SCFA pro-
duction and catabolism in relation to differences in
microbiome function using a larger group of healthy and
insulin-resistant subjects. Future research will thus have
to elucidate whether (short versus long term) treatment
with either oral SCFA or administration of speciﬁc
butyrate-producing intestinal bacteria has any therapeutic
potential in insulin-resistant subjects.
Disclaimer
There are no patents, products in development, or
marketed products to declare in relation to this study.
Study Highlights
What is current knowledge?
Short-chain fatty acids (SCFAs) are produced by
intestinal microbiota.
Animal models have shown that SCFA butyrate
improves glucose metabolism.
a b
Fig. 3 Correlation plots showing effect of oral butyrate on other biochemistry markers in both lean and metabolic syndrome subjects.
Correlation plots of fecal SCA, speciﬁc fecal bacterial strains, and clinical markers in a lean subjects and b insulin-resistant metabolic syndrome subjects.
Only signiﬁcant correlations after correction for multiple comparisons (p < 0.05) are depicted. Blue depicts positive correlation, whereas red color means
inverse correlation. The size and strength of the color depict the magnitude of the correlation
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SCFA butyrate treatment in animals increases brown
adipose tissue activation.
What is new here?
Oral butyrate suppletation only beneﬁcially affects
glucose metabolism in lean subjects.
In contrast to animal models, no effect on brown adipose
tissue was found in both lean and obese insulin-resistant
subjects.
Author details
1Department of Vascular Medicine, Academic Medical Center, Amsterdam, The
Netherlands. 2Department of Endocrinology, LUMC, Leiden, The Netherlands.
3Wallenberg Laboratory, Department of Molecular and Clinical Medicine,
Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
4Department of Internal Medicine, AMC, Amsterdam, The Netherlands.
5Department of Nuclear Medicine, AMC, Amsterdam, The Netherlands.
6Department of Endocrinology, AMC, Amsterdam, The Netherlands. 7Depart-
ment of Clinical Chemistry, Laboratory of Endocrinology, AMC, Amsterdam,
The Netherlands. 8Department of Clinical Pharmacy, AMC, Amsterdam, The
Netherlands. 9Department of Laboratory Medicine, University of Groningen,
UMCG, Groningen, The Netherlands. 10Department of Internal Medicine, VU
University Medical Center, Amsterdam, The Netherlands. 11ICAR, VU University
Medical Center, Amsterdam, The Netherlands
Competing interests
Guarantor of the article M. Nieuwdorp.
Speciﬁc author contributions M.N., A.K.G., J.A.R, F.B., and K.W.v.D. designed the
study. E.M.K. provided the GMP produced sodium butyrate capsules. K.E.C.B., G.J.
B., L.O., R.S.K., A.V.H., P.W.G, S.D.U, S.K., L.H., H.J.V., and L.B. performed the research.
V.T., M.S., F.H., H.J.V., N.A.W.v.R., M.T.A., M.J.S., and G.M.D.-T. provided analytic tools.
K.E.C.B., E.L., and V.T. performed the statistical analysis. K.E.C.B, A.K.G., F.B., and M.N.
drafted the paper. All authors critically reviewed the manuscript.
Financial support K.E.C.B. and S.K. are supported by an AMC-LUMC Rembrandt-
grant 2012. F.B. is supported by Swedish Research Council, Swedish Diabetes
Foundation, Swedish Heart Lung Foundation, Swedish Foundation for Strategic
Research, Knut and Alice Wallenberg foundation, Göran Gustafsson Foundation,
Ingbritt and Arne Lundberg’s foundation, Swedish Heart Lung Foundation,
Torsten Söderberg’s Foundation, Ragnar Söderberg’s Foundation, NovoNordisk
Foundation, AFA insurances, and LUA-ALF grants from Västra Götalandsregionen
and Stockholm County Council. F.B. is a recipient of ERC Consolidator Grant
(European Research Council, Consolidator grant 615362—METABASE). M.N. is
supported by a ZONMW-VIDI grant 2013 (016.146.327), ICAR Vu talent grant, and
CVON Young Talent grant 2012.
Potential competing interests’ F.B. is a founder and in the Scientiﬁc Advisory
Board of MetaboGen AB, Sweden. M.N. is the founder and in the Scientiﬁc
Advisory Board of Caelus Pharmaceuticals, the Netherlands. None of these are
directly relevant to the current paper. The remaining authors declare that they
have no conﬂict of interest.
Publisher's note Springer Nature remains neutral with regard to jurisdictional
claims in published maps and institutional afﬁliations.
Supplementary Information The online version of this article (https://doi.
org/10.1038/s41424-018-0025-4) contains supplementary material, which is
available to authorized users.
Received: 4 April 2018 Accepted: 22 April 2018
References
1. Chen, L., Magliano, D. J. & Zimmet, P. Z. The worldwide epidemiology of type
2 diabetes mellitus; present and future perspectives. Nat. Rev. Endocrinol. 8,
228–236 (2012).
2. Boyle, J. P. et al. Projection of the year 2050 burden of diabetes in the US adult
population: dynamic modeling of incidence, mortality, and prediabetes pre-
valence. Popul. Health Metr. 8, 29 (2010).
3. Group, T. A. S. Long-term effects of intensive glucose lowering on cardio-
vascular outcomes. N. Engl. J. Med. 364, 818–828 (2011).
4. Bouter, K. E. et al. Role of the gut microbiome in the pathogenesis of obesity
and obesity-related metabolic dysfunction. Gastroenterology 152, 1671–1678
(2017).
5. Canfora, E. E., Jocken, J. W. & Blaak, E. E. Short-chain fatty acids in control
of body weight and insulin sensitivity. Nat. Rev. Endocrinol. 11, 577–591
(2015).
6. Samuel, B. S. et al. Effects of the gut microbiota on host adiposity are
modulated by the short-chain fatty-acid binding G protein-coupled receptor.
Proc. Natl Acad. Sci. USA 105, 16767–16772 (2008).
7. Perry, R. J. et al. Acetate mediates a microbiome-brain-β-cell axis to promote
metabolic syndrome. Nature 534, 213–217 (2016).
8. Gao, Z. et al. Butyrate improves insulin sensitivity and increases energy
expenditure in mice. Diabetes 58, 1509–1517 (2009).
9. Li Z. et al. Butyrate reduces appetite and activates brown adipose tissue via
the gut-brain neural circuit. Gut 2017. pii: gutjnl-2017-314050. https://doi.org/
10.1136/gutjnl-2017-314050. [Epub ahead of print].
10. Ziętak, M. et al. Altered microbiota contributes to reduced diet-induced
obesity upon cold exposure. Cell Metab. 23, 1216–1223 (2016).
11. Owen, B. M., Mangelsdorf, D. J. & Kliewer, S. A. Tissue-speciﬁc actions of the
metabolic hormones FGF15/19 and FGF21. Trends Endocrinol. Metab. 26,
22–29 (2015).
12. Harms, M. & Seale, P. Brown and beige fat: development, function and ther-
apeutic potential. Nat. Med. 19, 1252–1263 (2013).
13. Vijgen, G. H. et al. Increase in brown adipose tissue activity after weight loss
in morbidly obese subjects. J. Clin. Endocrinol. Metab. 97, E1229–E1233
(2012).
14. Hanssen, M. J. W. et al. Short-term cold acclimation improves insulin
sensitivity in patients with type 2 diabetes mellitus. Nat. Med. 21, 863–865
(2015).
15. Eckel, R. H. et al. The metabolic syndrome. Lancet 375, 181–183 (2010).
16. Sabatino, A. D. et al. Oral butyrate for mildly to moderately active Crohn’s
disease. Aliment. Pharmacol. Ther. 22, 789–794 (2005).
17. Vrieze, A. et al. Transfer of intestinal microbiota from lean donors increases
insulin sensitivity in individuals with metabolic syndrome. Gastroenterology
143, 913–916.e7 (2012).
18. Steele, R. Inﬂuences of glucose loading and of injected insulin on hepatic
glucose output*. Ann. N. Y. Acad. Sci. 82, 420–430 (1959).
19. Admiraal, W. M. et al. Cold-induced activity of brown adipose tissue in young
lean men of South-Asian and European origin. Diabetologia 56, 2231–2237
(2013).
20. Alnouti, Y., Csanaky, I. L. & Klaassen, C. D. Quantitative-proﬁling of bile acids and
their conjugates in mouse liver, bile, plasma, and urine using LC–MS/MS. J.
Chromatogr. B 873, 209–217 (2008).
21. Hulzebos, C. V. et al. Measurement of parameters of cholic acid kinetics in
plasma using a microscale stable isotope dilution technique: application to
rodents and humans. J. Lipid Res. 42, 1923–1929 (2001).
22. Fuller, M. et al. The short-chain fatty acid receptor, FFA2, contributes to
gestational glucose homeostasis. Am. J. Physiol. Endocrinol. Metab. 309,
E840–E851 (2015).
23. Karlsson, F. H. et al. Gut metagenome in European women with normal,
impaired and diabetic glucose control. Nature 498, 99–103 (2013).
24. Zhang, J. et al. PEAR: a fast and accurate Illumina Paired-End reAd mergeR.
Bioinformatics 30, 614–620 (2014).
25. DeSantis, T. Z. et al. Greengenes, a chimera-checked 16S rRNA gene database
and workbench compatible with ARB. Appl. Environ. Microbiol. 72, 5069–5072
(2006).
26. Wang, Q. et al. Naive Bayesian classiﬁer for rapid assignment of rRNA
sequences into the new bacterial taxonomy. Appl. Environ. Microbiol. 73,
5261–5267 (2007).
27. Lozupone, C. & Knight, R. UniFrac: a new phylogenetic method for comparing
microbial communities. Appl. Environ. Microbiol. 71, 8228–8235 (2005).
28. Vazquez-Baeza, Y. et al. EMPeror: a tool for visualizing high-throughput
microbial community data. Gigascience 2, 16 (2013).
29. Haas, B. J. et al. Chimeric 16S rRNA sequence formation and detection in
Sanger and 454-pyrosequenced PCR amplicons. Genome Res. 21, 494–504
(2011).
Bouter et al. Clinical and Translational Gastroenterology  (2018) 9:155 Page 9 of 10
Ofﬁcial journal of the American College of Gastroenterology
30. Anderson, M. J. A new method for non-parametric multivariate analysis of
variance. Austral Ecol. 26, 32–46 (2001).
31. Kootte, R. S. et al. Improvement of insulin sensitivity after lean donor fecal
microbiota transplantation in subjects with metabolic syndrome is associated
with baseline intestinal microbiota composition. Cell Metab. 26, 611–619
(2017).
32. Botschuijver, S. et al. Intestinal fungal dysbiosis associates with visceral
hypersensitivity in patients with irritable bowel syndrome and rats. Gastro-
enterology 153, 1026–1039 (2017).
33. Boets, E. et al. Systemic availability and metabolism of colonic-derived short-
chain fatty acids in healthy subjects: a stable isotope study. J. Physiol. 595,
541–555 (2017).
34. Wolever, T. M. S. et al. Effect of rectal infusion of short chain fatty acids in
human subjects. Am. J. Gastroenterol. 84, 1027–1033 (1989).
35. Chambers, E. S. et al. Effects of targeted delivery of propionate to the human
colon on appetite regulation, body weight maintenance and adiposity in
overweight adults. Gut 64, 1744–1754 (2015).
36. van der Beek Christina, M. et al. Distal, not proximal, colonic acetate infusions
promote fat oxidation and improve metabolic markers in overweight/obese
men. Clin. Sci. 130, 2073–2082 (2016).
37. den Besten, G. et al. Gut-derived short-chain fatty acids are vividly assimilated
into host carbohydrates and lipids. Am. J. Physiol. Gastrointest. Liver Physiol. 305,
G900–G910 (2013).
38. Macfarlane, S. & Macfarlane, G. T. Regulation of short-chain fatty acid pro-
duction. Proc. Nutr. Soc. 62, 67–72 (2003).
39. den Besten, G. et al. Short-chain fatty acids protect against high-fat
diet–induced obesity via a PPARγ-dependent switch from lipogenesis to fat
oxidation. Diabetes 64, 2398–2408 (2015).
40. Freeland, K. R. & Wolever, T. M. S. Acute effects of intravenous and rectal
acetate on glucagon-like peptide-1, peptide YY, ghrelin, adiponectin and
tumour necrosis factor-α. Br. J. Nutr. 103, 460–466 (2009).
41. Venter, C. S., Vorster, H. H. & Cummings, J. H. Effects of dietary propionate on
carbohydrate and lipid metabolism in healthy volunteers. Am. J. Gastroenterol.
85, 549–553 (1990).
42. Todesco, T. et al. Propionate lowers blood glucose and alters lipid metabolism
in healthy subjects. Am. J. Clin. Nutr. 54, 860–865 (1991).
43. Fernandes, J., Vogt, J. & Wolever, T. M. S. Intravenous acetate elicits a greater
free fatty acid rebound in normal than hyperinsulinaemic humans. Eur. J. Clin.
Nutr. 66, 1029–1034 (2012).
44. van Eunen, K. et al. Biochemical competition makes fatty-acid β-oxidation
vulnerable to substrate overload. PLoS Comput. Biol. 9, e1003186 (2013).
45. Wolever, T. M., Spadafora, P. & Eshuis, H. Interaction between colonic acetate
and propionate in humans. Am. J. Clin. Nutr. 53, 681–687 (1991).
46. Elwood, J. C., Marcó, A. & Van Bruggen, J. T. Lipid Metabolism in the diabetic
rat: IV. Metabolism of acetate, acetoacetate, butyrate, and mevalonate in vitro.
J. Biol. Chem. 235, 573–577 (1960).
47. Sheng, L. et al. Hepatic inﬂammation caused by dysregulated bile acid
synthesis is reversible by butyrate supplementation. J. Pathol. 243, 431–441
(2017).
48. Belenguer, A. et al. Rates of production and utilization of lactate by microbial
communities from the human colon. FEMS Microbiol. Ecol. 77, 107–119 (2011).
49. Louis, P. & Flint, H. J. Formation of propionate and butyrate by the human
colonic microbiota. Environ. Microbiol. 19, 29–41 (2017).
50. Canfora, E. E. et al. Colonic infusions of short-chain fatty acid mixtures promote
energy metabolism in overweight/obese men: a randomized crossover trial.
Sci. Rep. 7, 2360 (2017).
Bouter et al. Clinical and Translational Gastroenterology  (2018) 9:155 Page 10 of 10
Ofﬁcial journal of the American College of Gastroenterology
